ClinicalTrials.gg
RecruitingNCT06604273INTERACTUpdated Sep 19, 2024

Unravelling Intestinal Fibrosis in Ulcerative Colitis

A Phase 2/3 interventional study of Fibroblast Activation Protein Inhibitor in Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD) and Fibroblast Activation Protein Inhibitor, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 2/3, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Apr 2024, registered Sep 2024).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Colitis, Ulcerative by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 1 open to participants now, 1 under way, 1 of them phase 3. Colitis, Ulcerative · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Started
2024
the only one that year
Phase 2/3
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Colitis, Ulcerative by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is the only one that started in 2024, is the only one in phase 2/3, and was the 11th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 11 studies in Colitis, Ulcerative by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Colitis, Ulcerative by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), or all of them as a file.
02

Study summary

The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Inflammatory Bowel Disease (IBD)
  • Fibroblast Activation Protein Inhibitor

Keywords

  • PET CT
  • FAPI
  • IBD
  • Ulcerative colitis
  • Filgotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with confirmed diagnosis of UC - Group 1 criterion: ≥18 years of age regardless of gender
  • Group 2 criterion: ≥30 years of age for males and ≥40 years of age for females
  • Active disease confirmed by endoscopy (endoscopic Mayo score ≥ 2)
  • Indication to start treatment with filgotinib

AND one of the following criteria:

  • Active disease confirmed by intestinal ultrasound (BWT > 3 mm in at least one bowel segment and at least one other pathological IUS parameter) or
  • Increased CRP (>5 mg/L) and/or fecal calprotectin levels (>250 mg/kg)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Unable to provide
  • Colorectal carcinoma or high-grade dysplasia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Group 2

    This group undergoes FAPi-PET CT imaging

    Diagnostic Test: Fibroblast Activation Protein Inhibitor

  • No intervention
    Group 1

    Does not undergo a FAPi scan

Interventions

  • Diagnostic testFibroblast Activation Protein Inhibitor

    PET CT imaging using the fibroblast activation protein inhibitor tracer

    Also known as: FAPi PET CT scan

06

What researchers measure

Primary outcomes

  1. Candidate fibrotic cellular pathways

    Identification of candidate fibrotic cellular pathways using single cell pathway analysis and mucosal biopsies from UC patients before and at week 24 weeks after treatment initiation with filgotinib.

    Time frame: From enrollment to end of study participation at 24 weeks

Secondary outcomes

  1. 68Ga-FAPi-PET/CT imaging feasibility

    Feasilibility 68Ga-FAPi-PET/CT imaging as biomarker to monitor in vivo fibrosis in UC. By detection of in vivo intestinal fibrosis by means of measuring 68Ga-FAPi uptake, both visually as semi-quantitatively, in UC patients using FAPi-PET/CT imaging at baseline and 24 weeks after treatment initiation with filgotinib.

    Time frame: From enrollment to end of study participation at 24 weeks

  2. Correspondance 68Ga-FAPi uptake and STAT expression

    To determine to what extent 68Ga-FAPi bowel uptake in UC patients corresponds to (phospohorylated and total) STAT gene and protein (i.e. down-stream JAK targets) expression

    Time frame: From enrollment to end of study participation at 24 weeks

  3. Correspondance 68Ga-FAPi uptake and clinical and endoscopic parameters

    To determine to what extent 68Ga-FAPi bowel uptake in UC patients corresponds to clinical and endoscopic changes after 24 weeks of treatment with filgotinib

    Time frame: From enrollment to end of study participation at 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Apr 3, 2024
Primary completionEst.
Oct 3, 2025
CompletionEst.
Apr 3, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06604273
Responsible party
Dalia Lartey (Drs, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Sep 19, 2024
Start date
Apr 3, 2024
Primary completion
Oct 3, 2025 (estimated)
Completion
Apr 3, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Dalia A Lartey, MD
Contact
d.a.lartey@amsterdamumc.nl
+31205668160
Kelly van Wijnbergen, Msc
Contact
k.vanwijnbergen@amsterdamumc.nl
+31205668160
Mark Lowenberg, MD PhD
principal investigator · Amsterdam University Medical Centers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion